Skip to main content
Premium Trial:

Request an Annual Quote

ChondroGene's Q2 Revenue Slides 42 Percent as R&D Grows and Losses Swell

NEW YORK (GenomeWeb News) – ChondroGene today said that second-quarter revenue slid 42 percent as R&D spending rose by nearly one-third and net losses swelled 160 percent.
 
Total receipts for the three months ended June 30 declined to CA$873,020 ($781,020) from CA$1.5 million year over year. ChondroGene said the current quarter’s results comprise a CA$679,228 amortized one-time payment from Pfizer as part of an R&D alliance penned in 2004 and around CA$194,000 in fee and service revenue.
 
R&D spending in the quarter increased to CA$2.1 million from CA$1.6 million in the year-ago period.
 
Second-quarter net loss surged to CA$1.9 million from CA$731,545 year over year, ChondroGene said.
 
The company said it had around CA$25.8 million in cash and equivalents as of June 30.

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.